Professor David Selwood, Chief Scientific Officer
Dr Selwood is a leading medicinal chemist with deep industry and academic experience. At Canbex, he is responsible for medicinal chemistry, manufacturing and preclinical studies. Dr Selwood started his career in industry with the Wellcome Foundation Ltd and then with GlaxoWellcome. As a senior research scientist, he worked on the anti-migraine compound zolmitriptan and a follow up compound GW4991. In 1995 he joined the Wolfson Institute for Biomedical Research at University College London UCL), where he leads a medicinal chemistry group. He is also co-founder of UCL medicinal chemistry spin-out NCE discovery Ltd, now Domainex.